Curated News
By: NewsRamp Editorial Staff
March 23, 2026
BioStem Appoints Financial Expert Jodi Ungrodt to Board Amid Growth Push
TLDR
- BioStem Technologies appoints SEC-qualified financial expert Jodi Ungrodt to its board, strengthening governance for business expansion and public market growth in 2026.
- Jodi Ungrodt brings 29 years of life sciences accounting experience from Ernst & Young to oversee BioStem's financial reporting and risk management as Audit Committee Chair.
- BioStem's appointment of an experienced financial leader supports their mission to advance regenerative medicine and improve patient outcomes with placental-derived tissue products.
- BioStem Technologies adds a financial expert with experience advising over 30 IPOs to its board during a pivotal growth phase in MedTech.
Impact - Why it Matters
This appointment matters because it signals BioStem Technologies' serious intentions to scale operations and potentially pursue more aggressive public market strategies in 2026. For investors, Ungrodt's SEC-qualified financial expertise and IPO advisory experience suggest the company may be preparing for significant capital raises or uplisting opportunities. For the medical community, this strengthened governance comes as BioStem expands its placental-derived products from chronic wound care into acute applications, potentially accelerating the availability of innovative regenerative medicine solutions. In the competitive MedTech sector, where regulatory compliance and financial transparency are critical, having a board member with Ungrodt's regulatory background could enhance BioStem's credibility with healthcare providers, regulators, and institutional investors alike. This move also reflects the growing importance of specialized financial leadership in life sciences companies navigating complex regulatory environments while pursuing expansion.
Summary
BioStem Technologies (OTC: BSEM), a leading MedTech company specializing in placental-derived products for advanced wound care, has announced a significant leadership appointment that signals strategic growth ambitions. The company has appointed Jodi Ungrodt, a seasoned financial expert with 29 years of accounting leadership at Ernst & Young, to its Board of Directors, where she will also serve as Chair of the Audit Committee effective March 18, 2026. Ungrodt brings extensive experience advising life sciences companies on IPOs, regulatory compliance, and business combinations, making her uniquely qualified under SEC, NYSE, and NASDAQ rules to guide BioStem during what Chairman and CEO Jason Matuszewski describes as a "pivotal time" for the company's expansion beyond chronic wound care and planned increased public market presence in 2026.
Ungrodt's appointment comes as BioStem positions itself as an emerging leader in placental and umbilical cord-derived tissue products, leveraging proprietary technologies like BioRetain®, CryoTek®, and SteriTek® to preserve tissue properties for clinical use. The company's portfolio includes Neox®, Clarix®, VENDAJE®, and American Amnion™ product lines used across various medical specialties. Ungrodt replaces former board member Brandon Poe, who transitioned to BioStem's chief financial officer role in August 2025, bringing his own 25 years of healthcare finance experience to the organization. This leadership transition occurs as BioStem continues conducting leading-edge research to expand scientific understanding of placental-derived products and bring new innovations to market.
The appointment reflects BioStem's commitment to strong corporate governance as it scales operations and innovates in the regenerative medicine space. Ungrodt's background includes serving as Audit Committee Chair for Feeding San Diego and as an Advisory Board Member for Life Science Cares, complementing her experience advising over 70 life sciences companies during her EY tenure. BioStem's quality management system has been accredited by the American Association of Tissue Banks, ensuring compliance with current Good Tissue Practices and Good Manufacturing Processes. For those interested in following company developments, BioStem encourages signing up for their email distribution list HERE and following them on social media platforms to stay informed about their progress in advancing wound care solutions and regenerative medicine technologies.
Source Statement
This curated news summary relied on content disributed by PRISM Mediawire. Read the original source here, BioStem Appoints Financial Expert Jodi Ungrodt to Board Amid Growth Push
